^
    Back
    Association details:
    Biomarker:HER-2 A775_G776insYVMA
    Cancer:Non Small Cell Lung Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor) +
    Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    JICC01.15 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study

    Published date:
    01/12/2021
    Excerpt:
    Patient characteristics at baseline and response for pyrotinib with apatinib...Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations.